The product will be sold through independent and major pharmacy retail chains across the country.
Creso co-founder and CEO Dr Miri Halperin Wernli said: “We are very excited that Pharma Dynamics managed such a great launch of cannaQIX®Regular, Cannamics in South Africa, providing a strong basis to enter further countries in Africa.”
Leading pharmaceutical company
Pharma Dynamics, a subsidiary of Lupin Limited (NSE:LUPIN), is a leading pharmaceutical company in South Africa and is ranked the fifth biggest generic pharmaceutical company in the country.
Pharma Dynamics leads with high-quality generics at affordable prices and is well-known for its investments into innovative wellness programs towards holistic healthcare.
Its growing over-the-counter range includes cold and flu, allergy, heartburn, and immune booster products.
The organisation also has a significant prescription portfolio with cardiovascular and central nervous system products consistently prescribed and recommended by leading doctors and pharmacists countrywide.
Cannamics has been developed to Good Manufacturing Practice standards and is produced in Switzerland by Creso’s partner, Swiss-based food, and pharma development company, Domaco, Dr. med Aufdermaur AG to the highest Swiss quality with a ‘Swiss Made’ label.
The standardised, user-friendly strength and formulation allows precise dosage control and the pastilles have a more palatable taste compared to oils, is glucose-free and contains no tetrahydrocannabinol (THC).
Pharma Dynamics business development head Tommy Scott said: “In spite of COVID-19 lockdown we managed to launch Cannamics, which brings recognised benefits in these difficult times.
“We are excited to enter this new category with such a renowned partner in the CBD space ”.
The launch is the latest step in Creso’s strategy to commercialise its CannaQIX® product range, with the company recently signing an agreement with DHS to enter the Brazilian retail market and launch the product by the fourth quarter of 2020.